SCHEMBL4314913

SCHEMBL4314913

Cc1ccsc1C(=O)Nc1cc(N2CCN(C)CC2)ccc1C=Cc1n[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.58
AURKB Q96GD4 3/20 0.58
FGFR1 P11362 1/20 0.43
FLT1 P17948 1/20 0.43
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GFER P55789 1/20 0.40
ACHE P22303 1/20 0.40
INSR P06213 3/20 0.39
ALK Q9UM73 3/20 0.39
SIRT6 Q8N6T7 1/20 0.39
F10 P00742 1/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
IGF1R P08069 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4314905 1.00 AURKA (0.58) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4321500 0.94 AURKA (0.53) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4321496 0.94 AURKA (0.53) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4313585 0.93 AURKA (0.60) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4313589 0.93 AURKA (0.60) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4320741 0.93 AURKA (0.60) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4320733 0.93 AURKA (0.60) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL5265469 0.93 AURKA (0.60) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4326949 0.93 AURKA (0.58) AURKAAURKBFGFR1FLT1NPC1
SCHEMBL4326955 0.93 AURKA (0.58) AURKAAURKBFGFR1FLT1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885FGFR1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.